Lilly scraps rheumatoid arthritis trial after interim review

Hanmi thinks the drug may still have a future in other indications and is talking to Lilly about the next steps. (Image: Eli Lilly)

Eli Lilly has halted a phase 2 rheumatoid arthritis trial after getting a mid-study glimpse at the data. The setback leaves Lilly and partner Hanmi Pharmaceutical to weigh whether it is worth moving the Bruton's TKI forward in other indications.

Hanmi disclosed the suspension of the trial in a statement to investors in Korea. The  statement said Lilly stopped the study after an interim review revealed the trial was unlikely to hit its efficacy goal. Lilly designed the 276-patient, placebo-controlled trial to show the drug, LY3337641, could drive a 20% or greater improvement on a rheumatoid arthritis symptom scale.

Lilly is yet to comment on the study. Hanmi thinks the drug may still have a future in other indications and is talking to Lilly about the next steps for the asset. Lilly highlighted the potential of LY3337641 in lupus, Sjögren's syndrome and other conditions when it landed rights to the TKI. But the clinical trial program has so far only tested it in healthy volunteers and rheumatoid arthritis patients.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Investors gave short shrift to Hanmi's attempts to downplay the significance of the trial cancellation, driving its stock down 10%. That slide led to reports in local publications including Korea Biomedical Review.

Both companies have other drugs to fall back on if LY3337641—also known as HM71224—ends up on the scrapheap. Hanmi has seven other assets in phase 2 and beyond, including a once-weekly GLP-1 receptor antagonist that has advanced into a phase 3 diabetes trial in partnership with Sanofi. 

For Lilly, LY3337641 was a relatively small bet. Lilly picked up the rights to LY3337641 outside of China and Korea for $50 million upfront in 2015. The deal also included $640 million in milestones. The company has multiple other immunology assets in its mid to late-phase pipeline, including JAK1/2 inhibitor baricitinib.     

Suggested Articles

By employing heart rate signals, physical activity and sleep quality, common Fitbit trackers may be able to predict the spread of the flu.

Nanox has raised $26 million to help fuel the development and commercialization of its Star Trek-inspired digital X-ray bed.

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.